A Response to “Letter to the Editor Regarding ‘Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison’”

অনুরূপ উপাদানগুলি

• A Response to “Letter to the Editor Regarding ‘Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison’”
  অনুযায়ী: Sonja Ständer, অন্যান্য
  প্রকাশিত: (2025-12-01)
• Letter to the Editor Regarding ‘Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis’
  অনুযায়ী: Mike Bastian, অন্যান্য
  প্রকাশিত: (2024-02-01)
• Letter to the Editor Regarding “Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo Adjusted Indirect Treatment Comparison”
  অনুযায়ী: Raj Chovatiya, অন্যান্য
  প্রকাশিত: (2025-12-01)
• Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis
  অনুযায়ী: Kim Rand, অন্যান্য
  প্রকাশিত: (2023-10-01)
• Dupilumab Versus Mepolizumab for COPD: Evaluating Efficacy Outcomes Using Placebo-Adjusted Indirect Treatment Comparison
  অনুযায়ী: Surya P. Bhatt, অন্যান্য
  প্রকাশিত: (2025-09-01)